Recently, several clinical trials have demonstrated that the addition of CDK4/6 selective inhibitors to endocrine therapy has improved progression-free survival as well as overall survival in patients with advanced breast cancer [83,84,85]. This evidence concerns the gene CDK4 and breast carcinoma.